Showing results (731-740 of 3,348) with videos related to

Sort By:
Pageof 335
Pharmacoeconomics|September 10, 2025
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing RegimensLeo Karlsson, Joseph Ciccolini, Rob Ter Heine, et al.
Pharmacoeconomics|September 19, 2025
Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple SclerosisLuca Prosperini, Vincenzo Brescia Brescia Morra, Carla Fornari, et al.
Pharmacoeconomics|June 23, 2025
Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of PembrolizumabAntal T Zemplenyi, Nai-Chia Chen, Kelly E Anderson, et al.
Pharmacoeconomics|July 2, 2024
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host PneumoniaAndrew J Sutton, Daniel S Lupu, Stephen P Bergin, et al.
Pharmacoeconomics|July 5, 2024
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing FrameworkR Douglas Scott, Steven D Culler, James Baggs, et al.
Pharmacoeconomics|April 3, 2024
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort StudyOlu Onyimadu, Nerys M Astbury, Felix Achana, et al.
Pharmacoeconomics|February 8, 2024
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or DepressionRachel O'Loughlin, Renee Jones, Gang Chen, et al.
Pharmacoeconomics|January 13, 2024
The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of LifeCate Bailey, Martin Howell, Rakhee Raghunandan, et al.
Pharmacoeconomics|September 9, 2024
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of BiasYankier Pijeira Perez, Dyfrig A Hughes
Pharmacoeconomics|September 20, 2024
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?Nicholas R Latimer, Kurt Taylor, Anthony J Hatswell, et al.
Pageof 335